#Bio-Thera #BAT2206 #Dr. Reddy's #China, India #Guangzhou, Hyderabad

Bio-Thera and Dr. Reddy's Collaborative Agreement for Biosimilars in Southeast Asia

In a significant move for the biopharmaceutical industry, Bio-Thera Solutions and Dr. Reddy's Laboratories have entered into an exclusive partnership aimed at bringing innovative biosimilars to the Southeast Asian market. This agreement covers BAT2206, a proposed biosimilar for Stelara® and BAT2506, a proposed biosimilar for Simponi®. The collaboration promises to enhance patient access to these vital treatments across several emerging markets.

Details of the Agreement

Under the terms of the agreement, Bio-Thera will spearhead the development, manufacturing, and supply of the biosimilars while Dr. Reddy's will focus on regulatory approvals and commercialization efforts. The territories included in this deal cover countries such as Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam. Notably, Dr. Reddy's also secured exclusive rights to BAT2206 in Colombia, signaling further potential in Latin American markets.

Dr. Shengfeng Li, CEO of Bio-Thera, expressed optimism about the partnership, emphasizing its importance for enhancing patient care in Southeast Asia. “This is our first partnership focused solely on Southeast Asia,” he stated, highlighting Dr. Reddy's suitability to navigate the challenges in this region effectively.

On the other hand, Dr. Reddy's CEO, M.V. Ramana, remarked on how this collaboration fits into their broader strategy to expand biosimilar offerings in emerging markets. He stated, “With our well-established commercial strengths in these markets, we look forward to addressing the unmet needs of patients with access to affordable medicines.”

About BAT2206 and BAT2506

BAT2206

BAT2206 aims to offer a biosimilar alternative to Janssen's Stelara®, a human monoclonal antibody designed to inhibit IL-12 and IL-23 activity. Disrupting the binding of these interleukins plays a significant role in managing autoimmune conditions like Crohn's disease and ulcerative colitis, conditions characterized by chronic inflammation. Stelara® is already approved in the EU for treating moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

BAT2506

Meanwhile, BAT2506 is a proposed biosimilar to Simponi® (golimumab), which also targets TNF-alpha, a key player in inflammatory responses. Simponi® is widely recognized for managing several autoimmune disorders, including rheumatoid arthritis and ulcerative colitis, and is accompanied by important warnings regarding severe infections and malignancy risks.

Bio-Thera and Dr. Reddy's Company Backgrounds

Bio-Thera Solutions, headquartered in Guangzhou, China, focuses on developing innovative therapies aimed at addressing severe medical conditions and unmet health needs globally. They have successfully advanced several candidates through late-stage clinical trials and have brought multiple products to market.

Dr. Reddy's Laboratories, founded in 1984 and based in Hyderabad, India, is a globally recognized pharmaceutical company committed to providing affordable medicines and innovative health solutions. With a robust portfolio including APIs, generics, biosimilars, and a focus on key therapeutic areas, Dr. Reddy's continues to cater to patients' needs across various countries.

Conclusion

This partnership is not just a strategic business move; it represents a hopeful leap towards ensuring that patients in Southeast Asia have improved access to essential and life-changing biologic therapies. As Bio-Thera and Dr. Reddy's navigate regulatory pathways and market experiences together, the future looks promising for the effectiveness and reach of biosimilar medications in the region. The collaboration reinforces the significance of innovation in improving healthcare outcomes for patients in emerging markets.